West Pharmaceutical Services (WST) return on equity (ROE)

Return on equity · fiscal 2025
15.5%

West Pharmaceutical Services (WST) earned a return on equity of 15.5% in fiscal 2025 (the year ended December 31, 2025). That is 2.8 percentage points lower than the 18.4% of fiscal 2024. Figures as of 17 Nov 2026, 20:29 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
15.5%
Change on fiscal 2024
−2.8 pts
Highest on record
28.3%fiscal 2021
Lowest on record
9.3%fiscal 2015
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

West Pharmaceutical Services return on equity (ROE), in more detail

Across the 18 fiscal years on record (2008–2025), the highest was 28.3% in fiscal 2021 and the lowest 9.3% in fiscal 2015. The fiscal 2025 figure is higher than in 65% of the 17 earlier fiscal years on record, whose median is 13.3%.

History · 18 fiscal years

Return on equity by fiscal year

West Pharmaceutical Services return on equity (ROE), year by year

West Pharmaceutical Services (WST) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202515.5% 2.8 pts down
202418.4% 2.2 pts down
202320.6% 1.2 pts down
202221.8% 6.5 pts down
202128.3% 9.7 pts up
202018.7% 3.3 pts up
201915.4% 0.5 pts up
201814.8% 3.0 pts up
201711.8% 1.1 pts down
201612.9% 3.5 pts up
20159.3% 3.9 pts down
201413.3% 0.9 pts up
201312.4% 1.3 pts up
201211.1% 0.5 pts down
201111.5% 1.1 pts up
201010.4% 2.1 pts down
200912.5% 5.1 pts down
200817.7%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of West Pharmaceutical Services and comparable companies
CompanyReturn on equityFiscal year
Labcorp Holdings LH10.2%2025
DexCom DXCM30.5%2025
Koninklijke Philips PHG8.2%2025
Roivant Sciences ROIV-6.6%2026
West Pharmaceutical Services WST15.5%2025
Quest Diagnostics DGX13.8%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on WST

West Pharmaceutical Services, figure by figure

West Pharmaceutical Services (WST) overview: price, valuation and scorecardAll health care companies by market value

West Pharmaceutical Services return on equity (ROE): questions and answers

What is West Pharmaceutical Services's return on equity?

West Pharmaceutical Services (WST) earned a return on equity of 15.5% in fiscal 2025 (the year ended December 31, 2025). That is 2.8 percentage points lower than the 18.4% of fiscal 2024.

Is West Pharmaceutical Services's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 65% of the 17 earlier fiscal years on record, whose median is 13.3%.

What are the highest and lowest return on equity figures on record for West Pharmaceutical Services?

Across the 18 fiscal years on record (2008–2025), the highest was 28.3% in fiscal 2021 and the lowest 9.3% in fiscal 2015.

How is West Pharmaceutical Services's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “West Pharmaceutical Services (WST) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/WST/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.